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ABSTRACT
While the function of progesterone receptor (PR) has been studied in the mouse 
vagina and uterus, its regulation and function in the cervix has not been described. 
We selectively deleted epithelial PR in the female reproductive tracts using the Cre/
LoxP recombination system. We found that epithelial PR was required for induction 
of apoptosis and suppression of cell proliferation by progesterone (P4) in the cervical 
and vaginal epithelium. We also found that epithelial PR was dispensable for P4 to 
suppress apoptosis and proliferation in the uterine epithelium. PR is encoded by the 
Pgr gene, which is regulated by estrogen receptor α (ERα) in the female reproductive 
tracts. Using knock−in mouse models expressing ERα mutants, we determined that the 
DNA−binding domain (DBD) and AF2 domain of ERα were required for upregulation of 
Pgr in the cervix and vagina as well as the uterine stroma. The ERα AF1 domain was 
required for upregulation of Pgr in the vaginal stroma and epithelium and cervical 
epithelium, but not in the uterine and cervical stroma. ERα DBD, AF1, and AF2 were 
required for suppression of Pgr in the uterine epithelium, which was mediated by 
stromal ERα. Epithelial ERα was responsible for upregulation of epithelial Pgr in the 
cervix and vagina. Our results indicate that regulation and functions of epithelial PR 
are different in the cervix, vagina, and uterus.
INTRODUCTION
Progesterone (P4) and estradiol (E2) are major 
ovarian steroid hormones crucial for the development 
and homeostasis of the female reproductive tract (i.e., 
uterus, cervix, and vagina) [1]. P4 and E2 function 
through progesterone receptor (PR) and estrogen receptor 
(ER), respectively. PR and ER are ligand−dependent 
transcription factors belonging to the nuclear receptor 
superfamily [1]. ERα and ERβ are encoded by Esr1 and 
Esr2, respectively [2]. ERα is the major ER subtype in 
the female reproductive tract of mice and humans [2-4]. 
ERα is composed of several distinct functional domains, 
N−terminal activation function 1 (AF1), DNA−binding 
domain (DBD), a hinge region, and C−terminal ligand−
binding domain containing the AF2. ERα activates its 
target gene expression by binding to estrogen response 
elements (EREs) through its DBD (classical mechanism) 
or other transcription factor (e.g., AP-1 and Sp-1) binding 
sites through protein−protein interactions (tethering 
mechanism) [2]. The Pgr gene coding for PR is a well−
known ERα target gene in the female reproductive 
tract [1, 5]; however, the mechanism of Pgr activation 
by ERα is poorly understood. Reporter assays using 
isolated regulatory sequences of the PGR gene have 
implicated both classical and tethering mechanism in the 
transcriptional activation of PGR in MCF7 breast cancer 
cells [6-9]. However, it is unclear whether it is relevant 
to the normal female reproductive tract and whether both 
pathways are important in the natural chromatin context. 
During the female sexual cycle in humans and 
rodents, an E2 surge promotes and a P4 surge inhibits 
epithelial cell proliferation in the reproductive tracts [10]. 
The uterine and vaginal epithelia consist of columnar 
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and squamous epithelial cells, respectively. The cervical 
epithelium, however, is composed of columnar and 
stratified squamous epithelial cells [11]. The hormone−
mediated regulation of epithelial cell proliferation in 
the reproductive tracts involves crosstalk between the 
stromal and epithelial compartment [12]. Epithelial ERα 
is dispensable for E2−induced proliferation of uterine 
columnar epithelial cells [13]. Stromal ERα is required 
for squamous epithelial cell proliferation in the cervix and 
vagina [14]. Epithelial PR is dispensable for P4−induced 
suppression of epithelial cell proliferation in the uterine 
tissue recombinants derived from neonatal mice [15]. P4 
suppresses apoptosis in the uterine epithelium, which is 
mediated by stromal PR [16]. While PR is expressed in 
the cervical stroma and epithelium [17], knowledge on the 
function of PR and effects of P4 in the cervix is limited. 
Using knock−in mice expressing mutant ERα 
lacking activities of DBD, AF1, or AF2, we show that all 
three domains are required for upregulation of Pgr in the 
cervical epithelium and vagina. We also show that AF1 
is dispensable for upregulation of Pgr in the cervical and 
uterine stroma. Unlike the uterus, P4 promotes epithelial 
apoptosis in the cervix and vagina. P4 inhibits E2−induced 
cervical and vaginal squamous cell proliferation. Using 
epithelial Pgr−deficient mice, we demonstrate that 
epithelial PR is required for P4−induced apoptosis and 
suppression of cell proliferation in the cervical and vaginal 
epithelium. Our results are the first to show different 
functions and regulation of epithelial PR in the cervix, 
vagina, and uterus under the same hormonal condition.
 RESULTS
Histological features of the female reproductive 
tract lacking epithelial PR
To interrogate a role of epithelial PR in responses 
of the female reproductive tract to P4, we made use of 
Wnt7a−Cre/Pgrf/f mice (referred to as Pgred/ed hereafter; 
ed, epithelial deletion). In these mice, PR expression was 
ablated in the epithelium, but not stroma, of the cervix, 
vagina, and uterus (Figure 1A). To characterize epithelial 
PR functions under the same hormonal condition, 
we treated ovariectomized mice with E2 and P4 for 7 
days. Seven−day treatment with E2 was required for 
the entire cervical epithelia to reach the full thickness 
(Supplementary Figure S1). Regions of the uterus, cervix, 
and vagina that were analyzed throughout the study are 
shown in Figure 1B. The cervical epithelia of vehicle−
treated Pgrf/f and Pgred/ed mice were thin (13.2 μm in 
average) and composed of 2−3 cell layers (Figure 1C). 
E2 increased the height of the cervical epithelium in Pgr
f/f 
(65.8 ± 4.2 μm) and Pgred/ed mice (66.6 ± 2.9 μm) (Figure 
1C). The cervical epithelium height in E2+P4−treated Pgr
f/f 
(57.5 ± 5.0 μm) and Pgred/ed mice (60.7 ± 4.6 μm) was 
not significantly different from genotype−matching mice 
treated with E2 alone. The nucleus/cytoplasm ratio (0.66 ± 
0.03) of cervical suprabasal cells in E2−treated Pgr
f/f mice 
was significantly smaller than the ratio (1.09 ± 0.06) in 
E2+P4−treated mice (P = 0.05). A similar difference was 
observed in Pgred/ed mice [0.66 ± 0.02 (E2) vs. 1.03 ± 0.01 
(E2+P4); P = 0.05]. Hydropic degeneration was prominent 
in the cervix of E2+P4−treated Pgr
f/f but not Pgred/ed mice 
(Figure 1C). E2 induced hyperplasia and keratinization in 
the vaginal epithelium of Pgrf/f and Pgred/ed mice (Figure 
1D). In the vaginal epithelium of E2+P4−treated Pgr
f/f 
mice, keratinization was absent and hydropic degeneration 
was observed (Figure 1D). Also found was infiltration 
of K14−negative non−epithelial cells (Supplementary 
Figure S2), which are likely neutrophils [18]. These P4−
induced histologic changes in the vaginal epithelium 
were absent in E2+P4−treated Pgr
ed/ed mice (Figure 1D). 
E2 induced hyperplasia in the uterine epithelium, which 
was reversed by P4 in both Pgr
f/f and Pgred/ed mice (Figure 
1E). Phenotypes described in this study are summarized 
in Table 1.
P4 fails to inhibit epithelial cell proliferation in the 
cervix and vagina, but not uterus of Pgred/ed mice
P4 inhibits epithelial cell proliferation in the female 
reproductive tract [15, 19]. We sought to determine 
whether epithelial PR is required for this effect. We 
analyzed expression of cell proliferation marker Ki67 
to measure cell proliferation. Less than 1% of cervical 
epithelial cells were proliferative in vehicle−treated Pgrf/f 
and Pgred/ed mice (Figure 2A-2B). E2−induced cervical 
epithelial cell proliferation was not different between the 
two genotypes. Compared to genotype−matching mice 
treated with E2 alone, cervical epithelial cell proliferation 
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in the basal layer was significantly decreased in E2+P4−
treated Pgrf/f but not Pgred/ed mice (Figure 2A-2B). Similar 
phenotypes were observed in the vaginal epithelium of 
Pgrf/f and Pgred/ed mice (Figure 2C-2D and Table 1). In the 
uteri of both Pgrf/f and Pgred/ed mice, E2−induced epithelial 
cell proliferation was significantly inhibited by P4 
(Figure 2E-2F). In both genotypes, however, stromal cell 
proliferation was increased in the uteri of E2+P4−treated 
mice compared to E2−treated mice (Figure 2F). Similar 
results were obtained in the columnar epithelium of the 
cervix (data not shown). These results indicate that, under 
the same hormonal condition, epithelial PR is required for 
P4−induced suppression of cell proliferation only in the 
cervical and vaginal squamous epithelium.
Epithelial PR is required for proper 
differentiation of cervical and vaginal squamous 
epithelial cells
Histological features observed in the cervical and 
vaginal epithelium (see Figure 1C-1D) suggested that 
P4 regulates differentiation of squamous cells. Thus, we 
carried out Alcian blue staining and immunohistochemistry 
for cytokeratin 10 (K10), squamous differentiation 
marker [20]. Alcian blue staining is typically used to 
detect cervical acidic mucins, which are expressed 
by differentiated cells [21]. As expected, E2 induced 
expression of K10 in the suprabasal layer in the cervical 
epithelia of Pgrf/f and Pgred/ed mice (Figure 3A). K10 
Figure 1: Histology of female reproductive tracts in epithelial PR−deficient mice treated with E2+P4. A. Epithelium−
specific deletion of PR. Serial sections of the cervix, vagina, and uterus were stained for PR (brown). Nuclei were counterstained with 
hematoxylin. Black lines separate cervical/vaginal squamous epithelium (ep) and uterine luminal (le)/glandular epithelium (ge) from stroma 
(st). Scale bar, 50 μm. B. Schematics of murine female reproductive tracts. All analyses were carried out with red−boxed areas of each 
tissue. Note that a region between the cervix and uterus is not annotated because there is no histological boundary. C.-E. Ovariectomized 
mice were treated with female sex hormones as indicated and paraffin sections of the cervix C., vagina D., and uterus E. were subjected 
to H&E staining. Black arrowheads in C. and D. indicate cells undergoing hydropic degeneration. Green arrowheads in D. indicate non−
epithelial cells. Representative images of each group are shown (n = 3-5). V, vehicle; E2, estradiol; P4, progesterone, Scale bar, 30 μm.
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expression was reduced in the cervical epithelia of E2+P4−
treated Pgrf/f and Pgred/ed mice, indicating that epithelial 
PR is dispensable for K10 suppression by P4. Alcian blue 
staining was prominent in the cervix of Pgrf/f mice treated 
with E2+P4, but absent in identically treated Pgr
ed/ed mice 
(Figure 3B). This result indicates that P4−promoted Alcian 
blue staining is dependent upon epithelial PR. P4 inhibited 
E2−induced K10 expression and increased Alcian blue 
staining in the vaginal epithelium of Pgrf/f but not Pgred/ed 
mice (Figure 3C-3D and Table 1). These results indicate 
that epithelial PR is required for P4−mediated regulation of 
squamous cell differentiation in the vagina to the greater 
extent than in the cervix. 
Figure 2: Epithelial PR is required for P4 to inhibit epithelial cell proliferation in the cervix and vagina, but not uterus. 
Ovariectomized mice were treated with female sex hormones as indicated. Paraffin sections of the cervix A., vagina C., and uterus E. 
were stained for Ki67 (green). Nuclei were stained with Hoechst 33342 (blue). Scale bars, 30 μm. Results were quantified as described in 
Materials & Methods. Quantified results of the cervix B., vagina D., and uterus F. are shown as mean ± S.E.M (n = 3-5 per group). *P ≤ 
0.01, **P ≤ 0.05. 
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Epithelial PR plays distinct roles in epithelial 
apoptosis in the lower and upper reproductive 
tracts
P4 inhibits apoptosis in the uterine epithelium [16]. 
We carried out TUNEL assays to determine the role of P4 
and epithelial PR in regulation of apoptosis in the cervix, 
vagina, and uterus. A few TUNEL−positive apoptotic cells 
were found in the cervical epithelium of vehicle− and E2−
treated Pgrf/f and Pgred/ed mice (Figure 4A-4B). Compared 
to E2−treated mice, the apoptotic index was increased in 
the cervical epithelium of E2+P4−treated Pgr
f/f but not 
Pgred/ed mice (Figure 4A-4B). Similar results were obtained 
in the vaginal epithelium (Figure 4C-4D and Table 1). E2 
induced apoptosis in the uterine epithelium regardless of 
the genotype, which was inhibited by P4 in both Pgr
f/f and 
Pgred/ed mice (Figure 4E-4F and Table 1). These results 
indicate that epithelial PR is required for P4−induced 
apoptosis in the epithelium of lower reproductive tracts 
(i.e., cervix and vagina), but dispensable for P4 to inhibit 
apoptosis in the uterine epithelium.
ERα DBD and AF2 are required for upregulation 
of Pgr in the cervix and vagina
ERα regulates transcription of Pgr in the vagina and 
uterus [5]. We found that E2 increased the Pgr mRNA level 
significantly in the cervix of Esr1+/+ but not Esr1−/− mice 
(Figure 5A). Similarly, PR protein was readily detected in 
cervical tissue extracts and paraffin sections derived from 
Esr1+/+ but not Esr1−/− mice (Figure 5B-5C). These results 
demonstrate that ERα activates transcription of Pgr in the 
cervix. To understand a mechanism of transcriptional 
activation of Pgr by ERα, we made use of knock−in 
mouse models expressing ERα mutant defective for DBD, 
AF1, or AF2 (Figure 5D). The AA allele expresses an 
ERα mutant (E207A/G208A) that lacks the ERE−binding 
activity [22]. The AF2 allele expresses ERα harboring 
L543A/L544A substitution mutations in the helix 12, 
which abrogates the AF2 function [23]. The neo allele 
has a neo cassette in the exon 2, which is designed to 
abrogate expression of ERα [24]. This allele, however, 
expresses truncated ERα proteins lacking the AF1 domain 
due to cryptic splicing events [25, 26]. PR expression was 
Figure 3: Epithelial PR is required for P4−mediated regulation of differentiation in the cervical and vaginal epithelium. 
Reproductive tracts were isolated from female mice that were ovariectomized and then treated as indicated. Representative images of each 
group are shown (n = 3). A. Epithelial PR is dispensable for suppression of K10 expression by P4 in the cervical epithelium. Cervical 
sections were stained for K10 (green) and nuclei were stained with Hoechst 33342 (blue). Dotted lines separate epithelium (ep) and stroma 
(st). Scale bar, 50 μm. B. Alcian blue staining is increased by P4 in an epithelial PR−dependent manner in the cervical epithelium. Cervical 
sections were stained with Alcian blue. Nuclei were counterstained with Nuclear Fast Red. Scale bar, 50 μm. C. Epithelial PR is necessary 
for suppression of K10 expression by P4 in the vaginal epithelium. Vaginal sections were stained for K10 (green) and nuclei were stained 
with Hoechst 33342 (blue). Scale bar, 50 μm. D. Alcian blue staining is increased by P4 in an epithelial PR−dependent manner in the vaginal 
epithelium. Vaginal sections were subjected to Alcian blue staining. Nuclei were counterstained with Nuclear Fast Red. Scale bar, 50 μm. 
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barely detectable in cervical tissue extracts obtained from 
Esr1AA/− and Esr1AF2/AF2 mice (Figure 5B). Similarly, E2 
failed to induce PR expression in the cervix of Esr1AA/− 
and Esr1AF2/AF2 mice (Figure 5C). Albeit reduced compared 
to Esr1+/+ mice, the PR level was increased in cervical 
tissue extracts from Esr1neo/neo mice compared to Esr1−/−, 
Esr1AA/−, and Esr1AF2/AF2 mice (Figure 5B). Upregulation of 
PR expression in the cervix of Esr1neo/neo mice was mostly 
Figure 4: Epithelial PR is required for P4−mediated regulation of apoptosis in the cervix and vagina, but not the uterus. 
Reproductive tracts were isolated from female mice that were ovariectomized and then treated as indicated. A. P4 induces apoptosis in the 
cervical epithelium through epithelial PR. Cervical sections were subjected to TUNEL staining (green). Nuclei were stained with Hoechst 
33342 (blue). Dotted lines separate epithelium (ep) and stroma (st). Scale bar, 50 μm. B. Results shown in A. were quantified. Results are 
shown as mean ± S.E.M (n = 3-5 per group). *P = 0.04. C. P4 induces apoptosis in the vaginal epithelium through epithelial PR. Vaginal 
sections were subjected to TUNEL staining (green). Scale bar, 50 μm. D. Results shown in C. were quantified and displayed as mean ± 
S.E.M (n = 3-5 per group). *P = 0.04. E. P4 prevents apoptosis in an epithelial PR−independent manner in the uterine epithelium. Uterine 
sections were subjected to TUNEL staining (green). Scale bar, 50 μm. F. Results shown in E. were quantified and displayed as mean ± 
S.E.M (n = 3 per group). *P = 0.05.
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Figure 5: Mechanisms of upregulation of Pgr by ERα in the cervix and vagina. A. Pgr is upregulated by E2−ERα in the 
cervix. Mice were ovariectomized and treated with E2 for 24 hr. The relative levels of Pgr mRNA were compared by qPCR. The value from 
vehicle−treated Esr1+/+ cervix was set at 1. Results are shown as mean ± S.E.M (n = 3). *P = 0.05. B. Upregulation of PR expression is 
absent in the cervix of Esr1AA/− and Esr1AF2/AF2 mice. Ovary−intact mice of indicated genotypes (8-12 weeks of age) were treated with E2 for 
3 days to synchronize mice at the estrus. Expression of PR in the cervix was determined by immunoblot. Pgr−/− tissue extracts were used as 
negative control. GAPDH was used as loading control. Results were taken from separate gels indicated by black boxes. Intervening lanes 
in a same gel were removed, which was indicated by vertical white lines. Representative results from more than 2 mice per genotype are 
shown. C. E2−induced PR expression is absent in the cervix of Esr1AA/− and Esr1AF2/AF2 mice. Ovariectomized mice (n = 3 per group) were 
treated with vehicle or E2 for 7 days. Cervical tissue sections were stained for PR (green). Nuclei were stained with Hoechst 33342 (blue). 
Dotted lines separate epithelium (ep) and stroma (st). Scale bar, 25 μm. D. Summary of ERα proteins expressed by Esr1 alleles used in the 
study. Asterisks denote locations of alanine substitution mutations. AF, activation function; DBD, DNA−binding domain; LBD, ligand−
binding domain. E. Esr1 is deleted in the cervical and vaginal epithelium. Cervical and vaginal sections (n= 3 per tissue) were stained 
for ERα (green). Nuclei were stained with Hoechst 33342 (blue). Scale bar, 50 μm. F.-G. Epithelial ERα is required for upregulation of 
epithelial Pgr in the lower reproductive tracts. Mice (n = 3 per group) were ovariectomized and treated with vehicle or E2. Tissue sections 
of the cervix F. and vagina G. were stained for PR (green). Nuclei were stained with Hoechst 33342 (blue). Scale bar, 50 μm. 
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restricted in the stroma (Figure 5C). E2 did not activate 
Pgr expression in the vagina of Esr1−/−, Esr1AA/−, Esr1AF2/
AF2, and Esr1neo/neo mice (Supplementary Figure S3). PR 
expression patterns were similar in the cervix and vagina 
of Esr2+/+ and Esr2−/− mice (Supplementary Figure S4), 
indicating that ERβ is not required for upregulation of 
Pgr. To determine whether stroma−epithelium cross talk 
is involved in upregulation of Pgr by E2−ERα, we used 
Wnt7a−Cre/Esr1f/f (referred to as Esr1ed/ed hereafter). 
ERα expression was efficiently ablated in epithelial but 
not stromal cells in the cervix and vagina of Esr1ed/ed 
mice (Figure 5E). While E2 induced PR expression in the 
cervical stroma of Esr1f/f and Esr1ed/ed mice, E2 failed to 
do so in the cervical epithelium of Esr1ed/ed mice (Figure 
5F). Similar results were obtained from the vagina (Figure 
5G). These results suggest that, in the cervix and vagina, 
E2−induced upregulation of Pgr is cell−autonomous and 
mediated commonly by ERα DBD (i.e., ERE−binding) 
and AF2. 
ERα DBD and AF2 are required for upregulation 
of stromal Pgr and downregulation of epithelial 
Pgr in the uterus
Consistent with previously published results 
[13], expression of ERα was lost in the epithelium but 
retained in the stroma of the Esr1ed/ed uteri (Figure 6A). 
While stromal PR expression was increased by E2 in the 
Esr1f/f and Esr1ed/ed uteri, E2 decreased the PR levels in 
the uterine epithelium in both genotypes (Figure 6B). 
This result confirmed the paracrine mechanism of Pgr 
downregulation by ERα in the uterine epithelium [5, 27]. 
Stromal upregulation and epithelial downregulation of 
Pgr by E2 were absent in the uterus of Esr1
−/−, Esr1AA/−, 
and Esr1AF2/AF2 mice (Figure 6C). As reported previously 
[5], E2 activated stromal Pgr expression but failed to 
downregulate epithelial Pgr in the uterus of Esr1neo/
neo mice (Figure 6C). In the Esr2−/− uterus, E2 increased 
and decreased stromal and epithelial PR expression, 
respectively (Supplementary Figure S4), indicating that 
Figure 6: Mechanisms of regulation of Pgr by ERα in the uterus. A. Esr1 is deleted in the uterine epithelium. Uterine sections (n 
= 3) were stained for ERα (green). Nuclei were stained with Hoechst 33342 (blue). Dotted lines separate luminal epithelium (le) and stroma 
(st). Glandular epithelia (ge) are circumscribed by red circles. Scale bar, 50 μm. B. E2 suppresses epithelial Pgr expression in the Esr1ed/
ed uteri. Mice (n = 3) were ovariectomized and treated with vehicle or E2. Uterine tissue sections were stained for PR (green). Nuclei were 
stained with Hoechst 33342 (blue). Dotted lines separate luminal epithelium (le) and stroma (st). Glandular epithelia (ge) are circumscribed 
by red circles. Note that E2 downregulates epithelial Pgr and upregulates stromal Pgr in both genotypes. Scale bar, 25 μm. C. ERα DBD 
and AF2 are required for Pgr regulation in the uterus. Mice were treated as described in B.. Uterine tissue sections (n = 3 per group) were 
stained for PR (green). Nuclei were stained with Hoechst 33342 (blue). Dotted lines are to separate luminal (le) and glandular epithelium 
(ge) from stroma (st). Scale bar, 30 μm. 
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ERβ is not required for regulation of Pgr in the uterus. 
These results indicate that the function of ERα DBD and 
AF2 in stromal cells is required for stromal upregulation 
and epithelial downregulation of Pgr in the uterus. 
We next analyzed binding of ERα to the Pgr 
gene using the previously published ERα ChIP−seq 
data [28, 29]. Approximately 200 kb upstream and 100 
kb downstream of the Pgr transcription start site (TSS) 
were analyzed for the binding of wild−type ERα. While 
there were two E2−independent ERα−binding peaks at the 
3’ end of the Pgr gene, E2 enhanced ERα binding to the 
intragenic regions and −72 kb and −155 kb cluster in the 
Esr1+/+ uterus (Figure 7A). E2 also increased RNA polII 
binding to the Pgr gene in the same tissue. While the −155 
kb cluster was closer to AK054106, E2 did not regulate this 
gene (data not shown). Notably, we identified predicted 
half or full EREs in all ERα−binding sites (Figure 7A). 
Consistently, in the uterus of Esr1AA/− mice, both E2−
dependent and −independent ERα binding to the Pgr locus 
were not observed (Figure 7A). Concordantly, E2−induced 
recruitment of RNA polII was absent in the Esr1AA/− uterus. 
We confirmed by ChIP followed by qPCR that E2 induced 
enrichment of ERα binding to the −62 kb region (7.1-fold) 
and intron 3-4 (6.2-fold) of Pgr in the uterus of Esr1+/+ but 
not Esr1AA/− mice (Figure 7B). These results suggest that, 
in the uterus, ERα activates transcription of Pgr mainly by 
binding to EREs.
DISCUSSION
P4 inhibits E2−promoted epithelial cell proliferation 
in the murine female reproductive tract [19, 30]. We 
showed that, under the same hormonal condition, epithelial 
PR was necessary for P4 to suppress E2−induced epithelial 
cell proliferation in the cervix and vagina, but dispensable 
in the uterus (Figure 2). It is shown that epithelial PR is 
required for P4−mediated inhibition of uterine epithelial 
cell proliferation [30]. This discrepancy may be due to 
differences in treatment design (P4 for 3 days and then 
E2+P4 for 1 day vs. E2+P4 for 7 days), E2 doses (50 ng vs. 
1 μg), mouse genetic background (B6.SJL.129 mixed vs. 
FVB) and/or housing environment. We note that 7−day 
treatment with E2 and P4 might be pharmacologic rather 
than physiologic. Nonetheless, we believe our results are 
biologically relevant because P4−mediated inhibition of 
uterine epithelial proliferation during pregnancy depends 
on Hand2 transcription factor [31]. Expression of Hand2 
depends on P4 and PR and is restricted in the uterine 
stroma [31].
P4 inhibited E2−induced apoptosis in the uterus 
of both Pgrf/f and Pgred/ed mice (Figure 4E-4F). It is 
consistent with that P4 prevents epithelial cell apoptosis 
in the tissue recombinant composed of Pgr+/+ stroma 
and Pgr−/− epithelium [16]. E2 induces apoptosis in 
the uterine epithelium of Esr1f/f and Esr1ed/ed mice [13]. 
These results suggest that stromal ERα promotes and 
stromal PR inhibits apoptosis of uterine epithelial cells. 
One possibility is that stromal PR activates expression 
Figure 7: ERα binding to EREs correlates with RNA polII recruitment to the Pgr locus in the uterus. A. E2 induces 
binding of ERα and RNA polII to Pgr in the uterus of Esr1+/+ but not Esr1AA/− mice. Recruitment of ERα and RNA polII to the Pgr locus 
was analyzed using ChIP−seq data available in Gene Expression Omnibus (Esr1+/+, GSE36455l; Esr1AA/−, GSE56466). Vertical blue lines 
at the top indicate locations of predicted EREs, which were identified using position weight matrix algorithm. Two peaks validated in B. are 
indicated by red asterisk. Pink boxes indicate −155 kb (1) and −72 kb cluster (2). B. Validation of E2−dependent enrichment of ERα at two 
candidate binding regions. Mice were ovariectomized and treated with vehicle or E2. Extracted chromatin was subjected to ERα ChIP and 
enrichment of approximately 62 kb upstream of the Pgr TSS and intron 3-4 were quantified by qPCR. Data normalized to % input DNA is 
shown as mean ± S.E.M. (n = 4-5). *P = 0.001; **P = 0.0005.
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of a paracrine factor(s) that promotes cell survival. PR 
interacts with ERα and modulates the function of ERα 
in breast cancer cells [32]. Another possibility is that PR 
interacts with ERα in uterine stromal cells and inhibits 
ERα−mediated expression of a pro−apoptotic secretory 
factor(s). In the rodent uterus, E2−induced hyperplasia 
is eliminated by apoptosis [33]. Perhaps, E2−induced 
apoptosis is to balance out E2−induced hyperproliferation 
of uterine epithelial cells. Consistent with this idea, the 
apoptotic index was correlated with the proliferative index 
in the uterine epithelium (Figure 2F and 4F). Unlike the 
uterus, P4 promoted apoptosis in the cervical and vaginal 
epithelium, which was dependent on epithelial PR (Figure 
4A-4D). Epithelial PR was necessary for P4 to increase the 
ratio of nucleus to cytoplasm and suppress expression of 
K10 in the vagina but not cervix (Table 1). These results 
reveal that epithelial PR is differentially required for P4 
responses of epithelial cells in the cervix, vagina, and 
uterus. 
Using mouse genetic models, we determined 
that ERE binding (i.e., classical mechanism) of ERα is 
required for upregulation of Pgr in the cervix, vagina, 
and uterus (Figure 5B-5D, 6C, 7 and Supplementary 
Figure S3). The ERα DBD mutant (E207A/G208A) 
has acquired the capability to bind hormone response 
elements such as progesterone response element [29]. We 
do not believe that the gain−of−function compromises 
our conclusion because this ERα mutant did not bind to 
the Pgr locus (Figure 7). It is possible that the ChIP−
seq analyses might have failed to identify weak ERα−
binding sites; thus, we cannot rule out a possibility 
that the ERα tethering mechanism also contributes to 
transcription of Pgr in the female reproductive tract. 
Knock−in mice expressing an ERα mutant defective for 
the tethering mechanism would be required to test this. 
Reporter assays have shown that AP-1 and Sp-1 sites at 
the promoter downstream are required for ERα−mediated 
PGR activation in MCF7 breast cancer cells [7, 8]. In the 
uterus, strong E2−induced DBD−dependent ERα binding 
occurred mostly at far upstream ( > 60 kb) of the Pgr gene 
(Figure 7A). Genome−wide enrichment of ERα binding 
to promoter−distal regions has been identified [28, 34]. 
ERE−dependent long−range activation of PGR by ERα 
has been demonstrated in MCF7 cells [6]. It is likely that 
ERα binding to Pgr in the uterus occurs in stromal cells 
because epithelial ERα was not required for upregulation 
of stromal Pgr and downregulation of epithelial Pgr 
(Figure 6B). We postulate that similar long−range 
regulation by ERα is involved in transcriptional activation 
of Pgr in the cervix and vagina. The AF2 domain was also 
required for upregulation of Pgr by ERα in the cervix, 
vagina, and uterus (Figure 5B-5D, 6C and Supplementary 
Figure S3). Upregulation of Pgr was evident in the 
cervical and uterine stroma, but not vagina of Esr1neo/
neo mice (Figure 5C, 6C and Supplementary Figure S3). 
In tissue recombinants derived from Esr1neo/neo mice, PR 
expression is induced by E2 in the uterine but not vaginal 
stroma [5]. These results indicate that (1) ERα DBD and 
AF2 are commonly required for activation of Pgr in 
the female reproductive tracts and (2) AF1 is required 
for upregulation of Pgr only in the vaginal and cervical 
epithelium and vaginal stroma. Differential requirement of 
ERα domains for activation of Pgr may be due to distinct 
chromatin structures in different tissues and cell types, 
which may require different coactivators [2, 35]. 
E2 suppressed expression of Pgr in the uterine 
epithelium via stromal ERα (Figure 6B), which is in 
agreement with other findings [5, 13]. Downregulation 
of Pgr in the uterine epithelium involves transcriptional 
repression [5, 27]. It is unlikely that the non−cell 
autonomous downregulation of Pgr is through a cell−
cell contact because epithelial and stromal cells are 
physically separated by the basement membrane. Thus, we 
postulate that a paracrine factor(s) produced by stromal 
cells is responsible for repression of Pgr in the uterine 
epithelium. ERα DBD, AF1, and AF2 were required for 
downregulation of Pgr in the uterine epithelium (Figure 
6C), further suggesting that ERα DBD, AF1, and AF2 are 
necessary for regulating expression of such a factor(s). 
The AP-1 site at the +745 bp region of PGR has been 
implicated in repression of PGR in MCF7 cells [9]. It is 
plausible that a paracrine factor activates AP-1, which 
in turn suppresses transcription of Pgr in the uterine 
epithelium. 
Our results demonstrate distinct functions of 
epithelial PR in the cervix, vagina, and uterus, suggesting 
that PR regulates unique sets of genes and pathways in 
these tissues. Warranted are further studies to identify PR 
target genes and pathways in the stroma and epithelium 
of these tissues. Our results also demonstrate unique 
mechanisms of Pgr regulation in the cervix, vagina, and 
uterus. Together, our results underscore the complexity of 




Investigation has been conducted in accordance 
with the ethical standards and according to national and 
international guidelines. All procedures were carried out 
according to animal protocols approved by the University 
of Houston Institutional Animal Care and Use Committee.
Mice and treatments
All Esr1 and Pgr mice as well as Esr2 knockout 
and Wnt7a-Cre transgenic mice were described previously 
[13, 22-24, 36-39], and genotyped by PCR. All mouse 
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strains except for Esr2 knockout mice (C57BL/6) were 
backcrossed to FVB at least 5 generations. Mice were 
ovariectomized at the age of 6-8 weeks and rested 
for 2 weeks. They were then i.p. injected with vehicle, 
17β-estradiol (E2) alone, or E2 (1 μg/day) plus P4 (1 mg/
day) for 7 days. 
Histological staining
The female reproductive tracts were harvested 24 
hours after final hormone injections and processed as 
described previously [19]. Hematoxylin & eosin (H&E) 
and Alcian blue staining were carried out as described 
previously [19].
Immunohistochemistry and immunoblot
Antibodies were purchased from Santa Cruz 
Biotechnology [ERα (H184), PR (H190) and GAPDH 
(V-18)], Thermo Scientific [Ki67 (clone SP6) and K10 
(clone DE-K10)], BioLegend (K14), GenDEPOT (HRP−
conjugated anti−rabbit/goat IgG), Life Technologies 
(Alexa488−conjugated anti−rabbit/mouse IgG) and 
Rockland Immunochemicals (biotinylated anti−rabbit 
IgG). For IHC, sections were deparaffinized, rehydrated, 
microwaved in 10 mM sodium citrate buffer (pH 
6.0) and incubated with primary antibodies diluted 
in blocking buffers (PR, 1:200 in 5% goat serum; 
ERα, 1:100 in 10% goat serum and 0.5% skim milk; 
Ki67, 1:100 in 10% goat serum; K10, 1:50 in 5% goat 
serum). After extensive washes, sections were incubated 
with Alexa488−conjugated anti−rabbit/mouse IgG or 
biotinylated anti−rabbit IgG followed by ABC complex 
(Vector Laboratories) as described previously [19]. For 
immunoblot, cervical tissue homogenates were resolved 
in 7.5% SDS−polyacrylamide gel and proteins were 
transferred to PVDF membranes. 
TUNEL assay
TUNEL staining was carried out using ApopTag 
Fluorescein in situ apoptosis detection kit (Millipore) 
according to the manufacturer’s instructions. 
Microscopy and digital image analyses
Stained tissue sections were visualized by an 
Olympus BX51 or a Nikon ECLIPSE Ti microscope, 
and photographed with a color camera (Olympus 
DP73) or cooled CCD monochrome cameras (Olympus 
XM10 and Photometrics CoolSNAP HQ2). Digital 
images were acquired with imaging software (Olympus 
cellSens Dimension and Nikon NIS-Elements AR). For 
quantification, images were acquired from 5 microscopic 
fields per tissue with a 20X objective lens, and cells were 
quantified using the counting function of the NIH ImageJ 
software. Typical ranges of total cell count per tissue 
were 400 - 600 in the basal layer and 1,500 - 2,000 in the 
suprabasal layers. 
Chromatin immunoprecipitation and quantitative 
real−time PCR
Chromatin was prepared from ovariectomized 
Esr1+/+ or Esr1AA/− uterus one hour after i.p. injection 
with saline or E2 (250 ng/mouse) and ERα was 
immunoprecipitated as described previously [29]. 
Candidate ERα−binding regions in the Pgr locus 
were amplified using qPCR as described previously 
[29]. Nanograms of amplimer DNA was calculated 
using a standard curve, and normalized to % input 
DNA for each sample. Primers for the −62 kb region 
were 5’-GGGTCGAAACTACCAGCTAAA-3’ 
(forward) and 5’-CAAAGGCTTGGACAAATGAA-3’ 
(reverse). Primers for intron 3-4 were 
5’-TCTGCTCCAATGACTGTGTTC-3’ (forward) 
and 5’-ATCACATGCACTGAGAAGATCA-3’ 
(reverse). To compare expression levels of Pgr 
mRNA in the cervix, qPCR was carried out using a 
SYBR Green detection method. The relative mRNA 
levels were calculated using the ∆∆Ct method 
with Ppia mRNA as control. Primers for Pgr were 
5’-CCAGCATGTCGTCTGAGAAA-3’ (forward) and 
5’-GCCTGGCTCTCGTTAGGAAG-3’ (reverse). Primers 
for Ppia were 5’-GGGTTCCTCCTTTCACAGAA-3’ 
(forward) and 5’-GATGCCAGGACCTGTATGCT-3’ 
(reverse). 
Statistical analyses
Wilcoxon rank sum test was used for analysis of 
cell proliferation and apoptosis. Student’s t-test or 2-way 
ANOVA with Fisher’s LSD was used for analysis of qPCR 
data.
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